On 3 June 2026, ImmuneOnco Biopharmaceuticals (Shanghai) Inc. filed its Monthly Return to the Hong Kong Stock Exchange, covering the period ended 31 May 2026.

Registered share capital remained at RMB 431.51 million, split between 420.48 million H shares and 11.03 million unlisted domestic shares, both with a par value of RMB 1.00.

Issued share capital was unchanged at 420.48 million H shares and 11.03 million unlisted shares, with no treasury shares reported.

The company confirmed compliance with the Main Board’s minimum public-float requirement, maintaining at least 25% of H-share free float.

No movements were recorded under share options, warrants, convertible instruments, or other share issuance arrangements during the month.

The filing was signed by Executive Director and Joint Company Secretary Guan Mei.